Citation

Babulal GM, Stout SH, Head D, Holtzman DM, Fagan AM, Morris JC, Roe CM. J. Alzheimers Dis. 2017; 58(3): 675-680.

Affiliation

Departments of Neurology, Washington University School of Medicine, St. Louis, MO, USA.

Copyright

(Copyright © 2017, IOS Press)

DOI

10.3233/JAD-170067

PMID

28453487

Abstract

We examined whether neuropsychiatric symptoms (NPS) interact with cerebrospinal fluid (CSF) biomarkers (amyloid-β42 [Aβ42], tau, phosphorylated tau181 [ptau181], tau/Aβ42, and ptau181/Aβ42) of Alzheimer's disease pathology to predict driving decline among cognitively-normal older adults (N = 116) aged ≥65. Cox proportional hazards models examined time to receiving a rating of marginal or fail on the driving test. Age, education, and gender were adjusted in the models. Participants with more abnormal CSF (Aβ42, tau/Aβ42, ptau181/Aβ42) and NPS were faster to receive a marginal/fail on the road test compared to those without NPS. NPS interact with abnormal CSF biomarkers to impact driving performance among cognitively-normal older adults.

Language: en

Keywords

Alzheimer’s disease; cerebrospinal fluid; depression; neuropsychology; noncognitive outcomes; preclinical